Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003115503 | SCV003788052 | uncertain significance | Immunodeficiency, common variable, 7 | 2022-08-06 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The lysine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. This variant has not been reported in the literature in individuals affected with CR2-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.006%). This sequence change replaces threonine, which is neutral and polar, with lysine, which is basic and polar, at codon 1069 of the CR2 protein (p.Thr1069Lys). |
Ambry Genetics | RCV003384356 | SCV004091969 | uncertain significance | Inborn genetic diseases | 2023-08-19 | criteria provided, single submitter | clinical testing | The c.3206C>A (p.T1069K) alteration is located in exon 19 (coding exon 19) of the CR2 gene. This alteration results from a C to A substitution at nucleotide position 3206, causing the threonine (T) at amino acid position 1069 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Genome- |
RCV003115503 | SCV004180458 | uncertain significance | Immunodeficiency, common variable, 7 | 2023-04-11 | criteria provided, single submitter | clinical testing |